Venous thromboembolism in COVID-19: A meta-summary of cases

Saudi Med J. 2022 Sep;43(9):979-990. doi: 10.15537/smj.2022.43.9.20220316.

Abstract

Objectives: To summarize cases of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) among coronavirus disease (COVID-19) patients and discuss their symptoms, diagnostic method, clinical features, and prognosis.

Methods: All major databases were searched for relevant studies published between December 1, 2019 and May 5, 2021.

Results: A total of 233 articles were identified, 22 describing 48 patients were included. A total of 79.1% had PE and 20.9% had DVT. Most patients were men, with a mean age of 56 years. Comorbidities were present in 70.8%, and 85.4% had at least one risk factor of VTE. 56.3% had received anticoagulation therapy. Most patients were treated in the general ward. Complications occurred in 27.1% of the patients, and recovery was achieved in 80.4%.

Conclusion: Venous thromboembolism must be suspected even in patients who had received prior anticoagulant regimens or in stable cases, especially in males, the elderly, and patients with comorbidities and high D-dimer levels.

Keywords: COVID-19; DVT; PE; VTE; deep venous; hypercoagulability; pulmonary embolism.

MeSH terms

  • Aged
  • COVID-19* / complications
  • Female
  • Fibrin Fibrinogen Degradation Products / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Embolism* / diagnosis
  • Pulmonary Embolism* / epidemiology
  • Pulmonary Embolism* / etiology
  • Venous Thromboembolism* / epidemiology
  • Venous Thromboembolism* / etiology
  • Venous Thrombosis*

Substances

  • Fibrin Fibrinogen Degradation Products